Severe Asthma
Conditions
Keywords
severe asthma, exhaled breath, biologics, monitoring
Brief summary
This study will evaluate the fluctuations of exhaled breath markers in patients with severe asthma on biologics. In the study, severe asthma patients will be followed up to 16 weeks monitoring lung function and inflammation through non-invasive technologies such as exhaled breath analysis (FeNO, GC-MS and EBC). A control group will be followed up to two weeks with the overall objective to indentify and evaluate the modifcations of markers of inflammation in patient under biologic treatment.
Interventions
DEVICEexhaled breath analysis
non invasive technology to measure components of exhaled breath
Sponsors
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Severe asthma diagnosis according to the latest recommendation * Eligible or in treatment with a biologic treatment for severe asthma * Able to follow istructions * Able and willing to sign the informed consent
Exclusion criteria
* Not able to perform lung function measurements and the procedures of the study * Acute respiratory or non respiratory infection (\<4 weeks) * Not willing to continue the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| evaluate the fluctuations of markers of inflammation in patients with severe asthma under biologic therapy | 16 weeks |
Secondary
| Measure | Time frame |
|---|---|
| evaluate whether the measurement of H2O2 could be considered as a marker of inflammation in severe asthma patients | 16 weeks |
Other
| Measure | Time frame |
|---|---|
| evaluate whether there are specific exhaled biomarkers useful to monitor patients with severe asthma on long-term treatment with biologics | 16 weeks |
Countries
Italy
Contacts
Primary ContactStefania Principe, PhD
Backup ContactCarmen Durante
Outcome results
None listed